Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS	23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 05:01:13 ON 22 MAR 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 05:01:32 ON 22 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 19, 2004 (20040319/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 05:01:36 ON 22 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 05:01:43 ON 22 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAR 2004 HIGHEST RN 665776-10-3
DICTIONARY FILE UPDATES: 19 MAR 2004 HIGHEST RN 665776-10-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\759.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak
G2 O,N,C

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 05:08:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8056 TO ITERATE

12.4% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 155742 TO 166498
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 05:08:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 161324 TO ITERATE

100.0% PROCESSED 161324 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.11

L3 21 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 159.62 160.10

FILE 'CAPLUS' ENTERED AT 05:08:34 ON 22 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Mar 2004 VOL 140 ISS 13
FILE LAST UPDATED: 21 Mar 2004 (20040321/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 10 L3

=> d l4 fbib ab hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:960938 CAPLUS
DN 138:337781
TI Efficient synthesis of a new potential chelating agent for radioimmunotherapy
AU Gouin, Sebastien G.; Gestin, Jean-Francois; Remaud, Patricia; Faivre-Chauvet, Alain; Meslin, Jean Claude; Deniaud, David
CS Laboratoire de Synthese Organique, UMR CNRS 6513, Faculte des Sciences et des Techniques, Nantes, 44072, Fr.
SO Synlett (2002), (12), 2080-2082
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 138:337781
AB The synthesis of a new rigid analog of cyclohexyl-TTHA, an efficient lanthanide ligand, as well as the first complexation trials are reported. This polyaminopolycarboxylic acid (I) was obtained in five steps from

o-phenylenediamine as starting product. The key intermediate was tetramine II, which after alkylation and hydrolysis gave I with ten coordination centers.

IT **518038-50-1P 518038-51-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of polyaminopolycarboxylic acid and its complexation with yttrium)

RN 518038-50-1 CAPLUS
CN Carbamic acid, [1,2-phenylenebis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 518038-51-2 CAPLUS
CN Carbamic acid, [1,2-phenylenebis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:462923 CAPLUS
DN 137:241208
TI Introduction of Lanthanide(III) Chelates to Oligopeptides on Solid Phase
AU Peuralahti, Jari; Hakala, Harri; Mukkala, Veli-Matti; Loman, Kristiina; Hurskainen, Pertti; Mulari, Outi; Hovinen, Jari
CS PerkinElmer Life Sciences Wallac Oy, Turku, FIN-20101, Finland
SO Bioconjugate Chemistry (2002), 13(4), 870-875
CODEN: BCCHES; ISSN: 1043-1802

PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:241208
AB The synthesis of oligopeptide building blocks for the introduction of nonluminescent and luminescent lanthanide(III) chelates to the oligopeptide structure on the solid phase is described. The oligopeptide conjugates synthesized were used in DELFIA-based receptor binding assay (motilin) as well as in LANCE time-resolved fluorescence quenching assay (caspase-3).
IT **450374-57-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nonluminescent and luminescent lanthanide(III) chelates and their incorporation in solid-phase peptide synthesis)
RN 450374-57-9 CAPLUS
CN 3-Oxa-6,9,12-triazatetradecan-14-oic acid, 6,9-bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-12-[[4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]methyl]-2,2-dimethyl-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:149241 CAPLUS
DN 136:340985
TI A Noncovalent Approach to Antiparallel β-Sheet Formation
AU Zeng, Huaqiang; Yang, Xiaowu; Flowers, Robert A. ,II; Gong, Bing
CS Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, NY, 14260, USA
SO Journal of the American Chemical Society (2002), 124(12), 2903-2910
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:340985
AB Four tripeptide chains, when attached to the same end of a hydrogen-bonded duplex peptides I·II (R = Me, iso-Bu; Ia has R = Me; Ib has R = iso-Bu; IIa has R = iso-Bu; IIb has R = Me) with the unsym., complementary sequences of ADAA/DADD, have been brought into proximity, leading to the formation of four hybrid duplexes, Ia·IIa, Ia·IIb, Ib·IIa, and Ib·IIb, each of which contains a two-stranded β-sheet segment. The extended conformations of the peptide chains were confirmed by 1D and 2D NMR. The peptide strands stay registered through hydrogen bonding and the β-sheets are stabilized by side chain interactions. Two-dimensional NMR data also indicate that the duplex template prevents further aggregation in the peptide segment. When the peptide chains are attached to the two different termini of the duplex template, NMR studies show the presence of a mixture with no clearly defined conformations. In the absence of the duplex template, the tripeptides are found to associate randomly. Finally, isothermal titration calorimetry studies revealed that the hybrid duplex Ia·IIa was more stable than either the duplex template or the peptides alone.
IT **416899-51-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydrogen-bonded duplex templates with peptide chains that form antiparallel β-sheet-like structures)
RN 416899-51-9 CAPLUS
CN Benzoic acid, 3-[[[[2-(octyloxy)-5-[(1-oxohexyl)amino]benzoyl]amino]acetyl]amino]-5-[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, octyl ester (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:553906 CAPLUS
DN 133:335443
TI Synthesis of model compounds for potential contrast agents containing phosphonate and peptide moieties
AU Shalem, Hutti; Shatzmiller, Shimon; Feit, Ben-Ami
CS School of Chemistry, The Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv-Jaffa, 69978, Israel
SO Perkin 1 (2000), (16), 2831-2837
CODEN: PERKF9
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 133:335443
AB The synthesis of di-Me 2-acetoxy-2-(2,4-diiodo-5-aminophenyl)ethylphosphonate (I) and di-Me 2-acetoxy-2-(2,4,6-triiodo-3,5-diaminophenyl)ethylphosphonate (II) is described. Several amido derivs. III [X = CO(CH2)nCO; n = 0, 2, 4, 6] and peptide derivs. IV (R = Boc-Ala-Ala-, Cbz-Gly-Gly-, Cbz-Leu-Gly-, Cbz-Gly-Ala-, Cbz-Ala-Val-) of these phosphonates were prepared These products are composed of a combination of structural/functional moieties which enable them to be potential nonionic, selective x-ray contrast agents.
IT **303183-55-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phosphonates and their peptide derivs. as potential nonionic, selective x-ray contrast agents)
RN 303183-55-3 CAPLUS
CN Carbamic acid, [[5-[1-(acetyloxy)-2-(dimethoxyphosphinyl)ethyl]-4,6-diiodo-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:535988 CAPLUS
DN 133:267133
TI New highly potent dipeptidic growth hormone secretagogues with low molecular weight
AU Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Hansen, Birgit Sehested; Lau, Jesper; Nielsen, Karin Kramer; Raun, Kirsten
CS Health Care Chemistry, Novo Nordisk A/S, Malov, 2760, Den.
SO European Journal of Medicinal Chemistry (2000), 35(6), 599-618
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal

LA English

AB Based on NN703, low mol. weight growth hormone secretagogues (GHSs) with a reduced number of hydrogen binding sites were designed by removal of the C-terminal amide group. The compds. were highly potent in combination with high efficacy in a rat pituitary cell assay, being characterized with EC50 values down to 0.8 nM. Selected compds. were tested in in vivo animal models. The oral bioavailability in dogs was 16-44%. Also, the ED50 values of the compds. were determined both in dog and swine.

IT **202811-34-5P 202811-36-7P 202811-38-9P**
297175-37-2P 297175-40-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and biol. activity of highly potent dipeptidic growth hormone secretagogues with low mol. wts.)

RN 202811-34-5 CAPLUS

CN Carbamic acid, [2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 202811-36-7 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202811-38-9 CAPLUS
CN Carbamic acid, [(3E)-5-[[(1R)-2-[[2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 297175-37-2 CAPLUS
CN Carbamic acid, [2-[[2-[2-(methylamino)ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 297175-40-7 CAPLUS
CN Carbamic acid, [2-[[2-[2-[methyl[(2R)-2-(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:233909 CAPLUS
DN 130:275757
TI Contrasting agent for infarct and necrosis imaging of heart and kidneys
IN Platzek, Johannes; Niedballa, Ulrich; Raduchel, Bernd; Ebert, Wolfgang; Weinmann, Hanns-Joachim
PA Schering A.-G., Germany
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916757	A1	19990408	WO 1998-EP5184	19980817
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1997-19744003A	19970926
	DE 19744003	A1	19990715	DE 1997-19744003	19970926
	CA 2304458	AA	19990408	CA 1998-2304458	19980817
				DE 1997-19744003A	19970926
				WO 1998-EP5184 W	19980817
	AU 9893428	A1	19990423	AU 1998-93428	19980817
				DE 1997-19744003A	19970926
				WO 1998-EP5184 W	19980817
	EP 1017684	A1	20000712	EP 1998-946346	19980817
	EP 1017684	B1	20021120		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DE 1997-19744003A	19970926

			WO 1998-EP5184 W 19980817
JP 2001518471	T2	20011016	JP 2000-513843 19980817
			DE 1997-19744003A 19970926
			WO 1998-EP5184 W 19980817
AT 228116	E	20021215	AT 1998-946346 19980817
			DE 1997-19744003A 19970926
			WO 1998-EP5184 W 19980817
PT 1017684	T	20030331	PT 1998-98946346 19980817
			DE 1997-19744003A 19970926
ES 2188011	T3	20030616	ES 1998-946346 19980817
			DE 1997-19744003A 19970926
US 6083479	A	20000704	US 1998-157959 19980922
			DE 1997-19744003A 19970926
NO 2000001556	A	20000523	NO 2000-1556 20000324
			DE 1997-19744003A 19970926
			WO 1998-EP5184 W 19980817

OS MARPAT 130:275757

AB 1,4,7,10-Tetraazacyclododecane derivs. and their rare earth complexes as novel compds. suitable as contrasting agents, in particular for infarct and necrosis imaging, are disclosed, as well as processes for preparing the same and pharmaceuticals containing these compds. Thus, sym-diethylenetriaminepentaacetic acid tetra-tert-Bu ester in presence of N-hydroxysuccimide in DMF was treated with dicylcohexylcardodiimide and subsequently with glycine in presence of Et3N to give 3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2-oxo-4-carboxy)butyl]-3,6,9-triazaundecane-1,11-dicarboxylic acid di-tert-Bu ester (I). I was reacted with 1,4,7,10-tetraazacyclododecane in DMF in presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-1,4,7,10-tetraazacyclododecane which was reacted with hexadecanoic acid in DMF to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-10-[N-n-hexadecanoyl]-1,4,7,10-tetraazacyclododecane (II). II in CF3CO2H reacted with Gd2O3 in presence of NaOH to give after deprotection the Na salt of the Gd complex of the deprotected II.

IT **192636-26-3P 192636-28-5P 222033-44-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reactant for preparation of rare earth complexes with alkylcarbonyl derivs. of tetraazacyclododecane as MRI contrast agents for myocardial infarction and renal ischemia)

RN 192636-26-3 CAPLUS

CN Benzoic acid, 3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-(9CI) (CA INDEX NAME)



RN 192636-28-5 CAPLUS
CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B







RN 222033-44-5 CAPLUS
CN Carbamic acid, [[10-(1-oxotetradecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]tris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B







RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:87706 CAPLUS
DN 128:154388
TI Preparation of peptide analogs with growth hormone releasing properties
IN Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning
PA Novo Nordisk A/S, Den.; Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803473	A1	19980129	WO 1997-DK314	19970717
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				DK 1996-803	A 19960722
	AU 9734346	A1	19980210	AU 1997-34346	19970717
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
	EP 923539	A1	19990623	EP 1997-930368	19970717
	EP 923539	B1	20020605		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
	US 5922770	A	19990713	US 1997-896550	19970717
				DK 1996-803	A 19960722
	JP 2000515517	T2	20001121	JP 1998-506465	19970717
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
	EP 1184370	A2	20020306	EP 2001-123155	19970717
	EP 1184370	A3	20020327		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DK 1996-803	A 19960722
				EP 1997-930368	A3 19970717
	AT 218537	E	20020615	AT 1997-930368	19970717
				DK 1996-803	A 19960722
				WO 1997-DK314	W 19970717
	ZA 9706371	A	19980122	ZA 1997-6371	19970718
				DK 1996-803	A 19960722
	US 6127354	A	20001003	US 1999-270862	19990317
				DK 1996-803	A 19960722
				US 1997-896550	A3 19970717
	US 6274584	B1	20010814	US 2000-619227	20000719
				DK 1996-803	A 19960722
				US 1997-896550	A3 19970717
				US 1999-270862	A3 19990317

OS MARPAT 128:154388

AB The present invention relates to novel peptide analogs of general formula I [A = X-A1; X = alkylene chain optionally substituted and/or optionally containing O, S, or C:C double bond; A1 = N-containing heterocycle, (aminoalkyl)phenyl, (aminoalkyl)thienyl; G = H, halo, C1-6 alkyl, aryl, C1-6 alkoxy, CONR39R40, (CH2)pNR39SO2R41, (CH2)pNR39COR40, (CH2)pOR41, (CH2)pO2CR40, CHR39R40, CONR39NR40R42, (CH2)pNR39CSNR40R42, (CH2)pNR39CONR40R42; R39, R40 = independently H, (un)substituted C1-6 alkyl, etc.; R41 = aryl-substituted C1-6 alkyl; R42 = C1-6 alkyl; L1, L2 = independently CR57, N; R57 = H, C1-6 alkyl (un)substituted with OH, halo, C1-6 alkoxy, aryl; D, E = independently H, alkoxy, aryl, heteroaryl; R1 = H, C1-6 alkyl; R2 = H, acyl, C1-6 alkyl; R1R2 may form alkylene bridge; R3, R4 = independently H, (un)substituted C1-6 alkyl; R3R4 = O, S; n, m, p = independently 0-3] pharmaceutical compns. containing them, a method of

stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent of growth of animals to increase their milk and wool production, or for the treatment of ailments, and to use of the compds. for the preparation of medicaments. Thus, peptidomimetic II was prepared by standard reactions from (R)-2-[N-tert-butoxycarbonyl-N-methylamino]-3-(2-naphthyl)propionic acid, N-methyl-N-phenethylamine, and (E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid. II and related peptide analogs were tested for growth hormone release in rat pituitary primary cultures in doses ranging from 10 pM to 100 mM. The prepared compds. were also tested for metabolic stability.

IT **202811-34-5P 202811-35-6P 202811-36-7P**
202811-37-8P 202811-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptide analogs with growth hormone releasing properties)

RN 202811-34-5 CAPLUS
CN Carbamic acid, [2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 202811-35-6 CAPLUS
CN Carbamic acid, [2-[[2-[2-(methylamino)ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 202811-36-7 CAPLUS
CN Carbamic acid, [(1R)-2-[[2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202811-37-8 CAPLUS
CN Carbamic acid, [2-[[2-[2-[methyl[2-(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202811-38-9 CAPLUS
CN Carbamic acid, [(3E)-5-[[(1R)-2-[[2-[2-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:500179 CAPLUS
DN 127:122137
TI Nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents
IN Schmitt-Willich, Heribert; Platzek, Johannes; Raduechel, Bernd; Weinmann, Hanns joachim; Ebert, Wolfgang; Misselwitz, Bernd; Muehler, Andreas; Frenzel, Thomas
PA Schering A.-G., Germany
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19549286	A1	19970626	DE 1995-19549286	19951222
	CA 2241187	AA	19970703	CA 1996-2241187	19961129
				DE 1995-19549286A	19951222
	WO 9723245	A1	19970703	WO 1996-EP5315	19961129
	W: AU, BG, BY, CA, CZ, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1995-19549286A	19951222
	AU 9710328	A1	19970717	AU 1997-10328	19961129
	AU 726034	B2	20001026		
				DE 1995-19549286A	19951222
				WO 1996-EP5315 W	19961129
	EP 868202	A1	19981007	EP 1996-941055	19961129
	EP 868202	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DE 1995-19549286A	19951222
				WO 1996-EP5315 W	19961129
	JP 2000510880	T2	20000822	JP 1997-523251	19961129
				DE 1995-19549286A	19951222
				WO 1996-EP5315 W	19961129

AT 222776	E	20020915	AT 1996-941055 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
RU 2197495	C2	20030127	RU 1998-113782 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
PT 868202	T	20030131	PT 1996-96941055 19961129 DE 1995-19549286A 19951222
ES 2181924	T3	20030301	ES 1996-941055 19961129 DE 1995-19549286A 19951222
SK 283334	B6	20030603	SK 1998-854 19961129 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
ZA 9610822	A	19970627	ZA 1996-10822 19961220 DE 1995-19549286A 19951222
US 5874061	A	19990223	US 1996-777666 19961220 DE 1995-19549286A 19951222
TW 520377	B	20030211	TW 1996-85115801 19961220 DE 1995-19549286A 19951222
US 6057419	A	20000502	US 1998-77773 19980604 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
BG 63105	B1	20010430	BG 1998-102565 19980619 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
NO 9802903	A	19980622	NO 1998-2903 19980622 DE 1995-19549286A 19951222 WO 1996-EP5315 W 19961129
AU 744292	B2	20020221	AU 2000-55021 20000830
AU 2000055021	A5	20001109	DE 1995-19549286A 19951222

AB Complexes containing (a) A[X[Y[Z(WKw)z]y]x]a ligands (A = N-containing cascade polymer core with a branching degree, X, Y = direct bond or repeating unit with branching degree x, y, resp., Z, W = repeating unit with branching degree z, w, resp., K = complex formers, a = 2-12, x, y, z, w = 1-4, ≥2 repeating units being different, 16 ≤ axyzw ≤ 64, and ≥1 of X, Y, Z, W being a 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane repeating unit), (b) ≥16 ions of metals with atom. nos. 20-29, 39, 42, 44, or 57-83, (c) optionally, an cation of (in)organic base, amino acid, or amino amide, and (d) optionally, acylated terminal amino group are are manufactured for use as pharmaceuticals and contrast agents in NMR tomog. and radiog. A typical complex was manufactured by reaction of HBr with benzyloxycarbonyl-blocked 36mer cascade polyamine prepared from N,N,N',N',N'',N''-hexakis(2-aminoethyl)trimesic acid core and 6 1-[5-(4-nitrophenoxy)-3-oxaglutaryl]-4,7,10-tris(N,N'-dibenzyloxycarbonyllysyl)-1,4,7,10-tetraazacyclododecane, reaction of the resulting 36-mer amine hydrobromide with 1-(3-aza-4-carboxy-2-oxobutyl)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, and complexation of the Na salt of the resulting ligand with Gd2O3.

IT **192636-26-3P 192636-27-4P 192636-28-5P 192636-29-6P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-26-3 CAPLUS

CN Benzoic acid, 3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 192636-27-4 CAPLUS
CN Carbamic acid, [[5-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 192636-28-5 CAPLUS
CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B







RN 192636-29-6 CAPLUS

CN Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **192636-30-9P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(complexing cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-30-9 CAPLUS

CN Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]-, polymer with N,N,N',N',N'',N''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide (9CI) (CA INDEX NAME)

CM 1

CRN 192636-29-6
CMF C93 H96 N16 O25

PAGE 1-A





CM 2

CRN 192635-87-3
CMF C21 H39 N9 O3 . x Br H



● x HBr

IT **192636-31-0DP**, gadolinium complexes
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-31-0 CAPLUS

CN Sodium(1+), [tris(1,1-dimethylethyl) 10-[1-methyl-2-[[2-(4-nitrophenoxy)-2-oxoethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate-κN1,κN4,κN7,κN10]-, bromide, polymer with N,N,N',N',N'',N''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide and [2-oxo-2-[4,7,10-tris[3,5-bis[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]acetic acid (9CI) (CA INDEX NAME)

CM 1

CRN 192636-29-6
CMF C93 H96 N16 O25

PAGE 1-A



PAGE 1-B







CM 2

CRN 192636-00-3
CMF C37 H60 N6 Na O11 . Br
CCI CCS



● Br^-

CM 3

CRN 192635-87-3
CMF C21 H39 N9 O3 . x Br H



● x HBr

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:32622 CAPLUS
DN 122:31918
TI Structure-activity relationships of double-strand RGD peptides as GPIIb/IIIa receptor antagonists
AU Ojima, Iwao; Dong, Qing; Eguchi, Masakatsu; Oh, Young-im; Amann, Clare M.; Coller, Barry S.
CS School. Medicine, State University New York, Stony Brook, NY, 11794, USA
SO Bioorganic & Medicinal Chemistry Letters (1994), 4(14), 1749-54
CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English
AB A series of new double-strand RGD peptides M(CO-Arg-Gly-Asp-Phe-OH)2 [M = (CH2)n, p-C6H4, n = 2-4] and (R-Arg-Gly-Asp-Phe-NH)2XZ [R = H, Me(CH2)4CO, Bz, 4-[HN:C(NH2)NH]C6H4CO-Ser; X = Lys, Orn, cis,cis-3,5-diaminocyclohexanecarbonyl, 3,5-(Gly-NH)2C6H3CO; Z = NH2, Gly-Arg-Gly-Asp-Phe-NH2, Arg-Gly-Asp-Phe-OH] were prepared and their inhibitory activities evaluated for platelet aggregation. Substantial

improvement in activity is observed with these novel RGD peptides in comparison with single-strand RGD peptides. The structure-activity relationships of these double-strand RGD peptides are discussed.

IT **159581-70-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deblocking, and peptide coupling of, with protected arginylglycylaspartic acid peptides)

RN 159581-70-1 CAPLUS

CN Benzoic acid, 3,5-bis[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1975:86615 CAPLUS

DN 82:86615

TI Intramolecular rearrangements in peptide derivatives of anthranilic acid

AU Noguchi, Junzo; Kawai, Megumi; Hamada, Masato

CS Fac. Sci., Hokkaido Univ., Sapporo, Japan

SO Israel Journal of Chemistry (1974), 12(1-2), 87-101
CODEN: ISJCAT; ISSN: 0021-2148

DT Journal

LA English

AB The peptidylanthranilic acid ester is stable during peptide coupling. However, the amide bond of peptidylanthranilic acid is catalytically hydrolyzed at pH 7. In this reaction, no decomposition or significant racemization of peptide was observed and the protected peptide was easily obtained. Only glycylanthraniloyl derivs. rearranged into peptide and anthranilic acid in aqueous solution

IT **55301-22-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55301-22-9 CAPLUS

CN Carbamic acid, [2-oxo-2-[[2-[[[2-[[(phenylmethoxy)carbonyl]amino]ethyl]amino]carbonyl]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



=>